)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Theratechnologies
Theratechnologies (TH) investor relations material
Theratechnologies has been acquired
Theratechnologies EGM 2025 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.EGM 2025 summary12 Sep, 2025
Opening remarks and agenda
Meeting convened to consider a single agenda item: approval of a statutory plan of arrangement involving CB Biotechnology, an affiliate of Future Pak.
Meeting held both in person and virtually, with key executives present and procedures for orderly conduct outlined.
Notice and proxy materials were mailed to shareholders, and proof of service was annexed to the minutes.
Quorum confirmed with over 10% of voting shares represented.
Specific resolutions to be voted on
Special resolution to approve the arrangement, granting $3.01 per share in cash plus one Contingent Value Right (CVR) per share, less withholdings.
Each CVR entitles holders to up to $1.19 in additional cash if milestones are met within 36 months post-closing.
Corporate governance
Board unanimously determined the arrangement is in the best interest of shareholders and recommended voting in favor.
Fairness opinions provided by Barclays and Raymond James concluded the consideration is fair from a financial perspective.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Theratechnologies
- Revenue fell year-over-year, but operational recovery and acquisition signal renewed momentum.TH
Q2 2025 - Achieved financial turnaround and pipeline expansion in HIV, rare diseases, and oncology.THCorporate Presentation
- Q3 profit and raised EBITDA guidance highlight strong EGRIFTA SV growth despite supply issues.THQ3 2024
- Q2 delivered revenue growth, first net profit in years, and reaffirmed strong 2024 guidance.THQ2 2024
- All agenda items, including director elections and incentive plan, passed with strong support.THAGM 2025
- Q1 revenue up 17% to $19M; FDA approvals, EGRIFTA SV rebound, and 2025 guidance at $80–83M.THQ1 2025
- Record revenue and $20.2M EBITDA achieved, but supply and regulatory risks persist.THQ4 2024
Theratechnologies
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in cardiology, oncology, and women's health. The company primarily develops peptide-based therapeutics. Its product candidates include Onbrez Breezhaler, which is in Phase III clinical trial for the symptomatic relief of chronic obstructive pulmonary disease; and Theratears for Atopic Keratoconjunctivitis (MK), which is under Phase III clinical trial for the treatment of atopic keratoconjunctivitis. Theratechnologies Inc is headquartered in Montreal, Canada.